Table 1.

Drugs, doses and administration procedures used.

Drug	Mechanism	Suppliera	Route	Dosesb	Vehicle	Timec	Reference
Catalepsy studies
Haloperidol	DA antagonist	Sigma–Aldrich	i.p.	1.5	8.5% lactic acid	90	Jones et al. (2012)
LSP1-2111	mGluR4 agonist	VCNDDd	i.p.	0.3–30	Sterile water	30	Beurrier et al. (2009)
VU0364770	mGluR4 PAM	VCNDDd	s.c.	1–100	10% Tween 80	30	Jones et al. (2012)
A2A	A2A antagonist	VCNDDd	p.o	56.6	8.5% lactic acid		Jones et al. (2012)
Studies in 6-OHDA rats
l-DOPA methyl ester	DA precursor	Research Organics Inc.	s.c.	6	Saline	0	Lindgren et al. (2010)
Benserazide-HCl	DOPA decarboxylase inhibitor	Sigma–Aldrich	s.c.	12	Saline	0	Lindgren et al. (2010)
VU0364770	mGluR4 PAM	VCNDDd	p.o. or s.c.e	100	10% Tween 80 or 1:10 DMSO/PEGf	0	Jones et al. (2012)
LSP1-2111	mGluR4 agonist	VCNDDd	i.p.	15	Sterile water	0	Beurrier et al. (2009)

^aSource of the compounds used in this study.

^bDoses in mg/kg.

^cTime interval relative to testing.

^dVCNDD: Vanderbilt Center for Neuroscience Drug Discovery.

^es.c. route for experiment 1 and 4. p.o. route for experiments 2 and 3.

^f10% Tween vehicle for experiment 1 and 4, DMSO/PEG 1:10 vehicle for experiments 2 and 3.